Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Hareth Nahi, Saad Z. Usmani, Maria-Victoria Mateos, Niels W. C. J. van de Donk, Albert Oriol, Torben Plesner, Nibedita Bandyopadhyay, Peter Hellemans, Brenda Tromp, Ivo Nnane, Donna Zemlickis, Ajai Chari & Philippe Moreau. (2023) Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study. Leukemia & Lymphoma 64:2, pages 468-472.
Read now
Read now
Krishna Sury & Mark A. Perazella. (2019) The nephrotoxicity of new immunotherapies. Expert Review of Clinical Pharmacology 12:6, pages 513-521.
Read now
Read now
Utkarsh H. Acharya, Tejaswini Dhawale, Seongseok Yun, Caron A. Jacobson, Julio C. Chavez, Jorge D. Ramos, Jacob Appelbaum & David G. Maloney. (2019) Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. Expert Review of Hematology 12:3, pages 195-205.
Read now
Read now
Articles from other publishers (36)
Margaret M. Billingsley, Ningqiang Gong, Alvin J. Mukalel, Ajay S. Thatte, Rakan El‐Mayta, Savan K. Patel, Ann E. Metzloff, Kelsey L. Swingle, Xuexiang Han, Lulu Xue, Alex G. Hamilton, Hannah C. Safford, Mohamad‐Gabriel Alameh, Tyler E. Papp, Hamideh Parhiz, Drew Weissman & Michael J. Mitchell. (2023) In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism. Small.
Crossref
Crossref
Ajay S. Thatte, Alex G. Hamilton, Benjamin E. Nachod, Alvin J. Mukalel, Margaret M. Billingsley, Rohan Palanki, Kelsey L. Swingle & Michael J. Mitchell. (2023)
mRNA Lipid Nanoparticles for
Ex Vivo
Engineering of Immunosuppressive T Cells for Autoimmunity Therapies
. Nano Letters 23:22, pages 10179-10188.
Crossref
Crossref
Sophia Huang, Dorine de Jong, Jeeban P. Das, Reginald Scott Widemon, Brian Braumuller, Jacienta Paily, Aileen Deng, Connie Liou, Tina Roa, Alice Huang, Hong Ma, Belinda D’Souza, Jay Leb, Jade L’Hereaux, Pamela Nguyen, Lyndon Luk, Mark Francescone, Randy Yeh, Valerie Maccaronne, Laurent Dercle, Mary M. Salvatore & Kathleen M. Capaccione. (2023) Imaging the Side Effects of CAR T Cell Therapy: A Primer for the Practicing Radiologist. Academic Radiology.
Crossref
Crossref
Muriel F. Gustà, Michael J. Edel, Vivian A. Salazar, Belén Alvarez-Palomo, Manel Juan, Massimo Broggini, Giovanna Damia, Paolo Bigini, Alessandro Corbelli, Fabio Fiordaliso, Alexander Barbul, Rafi Korenstein, Neus G. Bastús & Víctor Puntes. (2023) Exploiting endocytosis for transfection of mRNA for cytoplasmatic delivery using cationic gold nanoparticles. Frontiers in Immunology 14.
Crossref
Crossref
Komal Paradkar, Andrew Krispinsky & Brittany Dulmage. (2022)
Cystic degeneration of a lipoma in a patient treated with
CAR‐T
therapy
. International Journal of Dermatology 62:3.
Crossref
Crossref
Qiang Zeng, Zhigang Liu, Ting Niu, Chuan He, Ying Qu & Zhiyong Qian. (2023) Application of nanotechnology in CAR-T-cell immunotherapy. Chinese Chemical Letters 34:3, pages 107747.
Crossref
Crossref
Lili Li, Luqin Wang, Qinhua Liu, Zhonghui Wu, Yulong Zhang & Ruixiang Xia. (2022) Efficacy and safety of CD22-specific and CD19/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis. Frontiers in Oncology 12.
Crossref
Crossref
Gulrayz Ahmed, Bhavna Bhasin-Chhabra, Aniko Szabo, Nirav N. Shah, Walter Longo, Binod Dhakal, Saurabh Chhabra, Anita D'Souza, Timothy S. Fenske & Mehdi Hamadani. (2022) Impact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients. Clinical Lymphoma Myeloma and Leukemia 22:11, pages 863-868.
Crossref
Crossref
Zimeng Fan, Zhian Li & Liwen Sun. (2022) Effectiveness of Cytokine-Related Combination Immunotherapy with Conventional Oncological Treatment. Highlights in Science, Engineering and Technology 8, pages 121-126.
Crossref
Crossref
Vardges Tserunyan & Stacey D. Finley. (2022) Modelling predicts differences in chimeric antigen receptor T-cell signalling due to biological variability. Royal Society Open Science 9:8.
Crossref
Crossref
Ajeet Gajra, Abigail Zalenski, Aishwarya Sannareddy, Yolaine Jeune-Smith, Kandice Kapinos & Ankit Kansagra. (2022) Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice. Pharmaceutical Medicine 36:3, pages 163-171.
Crossref
Crossref
Mohadeseh Mirzaee Godarzee, Bashdar Mahmud Hussen, Ehsan Razmara, Benyamin Hakak‐Zargar, Fatemeh Mohajerani, Hamed Dabiri, Mohammed Fatih Rasul, Mohammad Hossein Ghazimoradi, Sadegh Babashah & Majid Sadeghizadeh. (2022) Strategies to overcome the side effects of chimeric antigen receptor T cell therapy. Annals of the New York Academy of Sciences 1510:1, pages 18-35.
Crossref
Crossref
Margaret M. Billingsley, Alex G. Hamilton, David Mai, Savan K. Patel, Kelsey L. Swingle, Neil C. Sheppard, Carl H. June & Michael J. Mitchell. (2021) Orthogonal Design of Experiments for Optimization of Lipid Nanoparticles for mRNA Engineering of CAR T Cells. Nano Letters 22:1, pages 533-542.
Crossref
Crossref
Silpita Paul & Gaurisankar Sa. (2021) Curcumin as an Adjuvant to Cancer Immunotherapy. Frontiers in Oncology 11.
Crossref
Crossref
Maryam Akhoundi, Mahsa Mohammadi, Seyedeh Saeideh Sahraei, Mohsen Sheykhhasan & Nashmin Fayazi. (2021) CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities. Cellular Oncology 44:3, pages 495-523.
Crossref
Crossref
Zuyuan Luo, Zhen Liu, Zhen Liang, Jijia Pan, Jun Xu, Jiebin Dong, Yun Bai, Hongkui Deng & Shicheng Wei. (2020) Injectable Porous Microchips with Oxygen Reservoirs and an Immune-Niche Enhance the Efficacy of CAR T Cell Therapy in Solid Tumors. ACS Applied Materials & Interfaces 12:51, pages 56712-56722.
Crossref
Crossref
Marcela V Maus, Sara Alexander, Michael R Bishop, Jennifer N Brudno, Colleen Callahan, Marco L Davila, Claudia Diamonte, Jorg Dietrich, Julie C Fitzgerald, Matthew J Frigault, Terry J Fry, Jennifer L Holter-Chakrabarty, Krishna V Komanduri, Daniel W Lee, Frederick L Locke, Shannon L Maude, Philip L McCarthy, Elena Mead, Sattva S Neelapu, Tomas G Neilan, Bianca D Santomasso, Elizabeth J Shpall, David T Teachey, Cameron J Turtle, Tom Whitehead & Stephan A Grupp. (2020) Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. Journal for ImmunoTherapy of Cancer 8:2, pages e001511.
Crossref
Crossref
Hua Zhou, Min Yang, Li Cui & Jingting Jiang. (2020) Chimeric antigen receptor T cell therapy and nephrotoxicity: From diagnosis to treatment strategies. International Immunopharmacology 89, pages 107072.
Crossref
Crossref
Scott W. Canna & Rebecca A. Marsh. (2020) Pediatric hemophagocytic lymphohistiocytosis. Blood 135:16, pages 1332-1343.
Crossref
Crossref
Amanda M. Rivera, Scott May, Matthew Lei, Stephanie Qualls, Katelyn Bushey, Daniel B. Rubin & Megan E. Barra. (2020) CAR T-Cell-Associated Neurotoxicity. Critical Care Nursing Quarterly 43:2, pages 191-204.
Crossref
Crossref
Cristina GutierrezColleen McEvoyLaveena MunshiR. Scott StephensMichael E. DetskyJoseph L. NatesStephen M. Pastores. (2020) Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer. Critical Care Medicine 48:1, pages 10-21.
Crossref
Crossref
DANIELLE L. SALY & MARK A. PERAZELLA. 2020. Onco-Nephrology. Onco-Nephrology
166
182.e3
.
DaMarcus E. Baymon & Edward W. Boyer. (2019) Chimeric antigen receptor T-cell toxicity. Current Opinion in Pediatrics 31:2, pages 251-255.
Crossref
Crossref
Kris M. Mahadeo, Sajad J. Khazal, Hisham Abdel-Azim, Julie C. Fitzgerald, Agne Taraseviciute, Catherine M. Bollard, Priti Tewari, Christine Duncan, Chani Traube, David McCall, Marie E. Steiner, Ira M. Cheifetz, Leslie E. Lehmann, Rodrigo Mejia, John M. Slopis, Rajinder Bajwa, Partow Kebriaei, Paul L. Martin, Jerelyn Moffet, Jennifer McArthur, Demetrios Petropoulos, Joan O’Hanlon Curry, Sarah Featherston, Jessica Foglesong, Basirat Shoberu, Alison Gulbis, Maria E. Mireles, Lisa Hafemeister, Cathy Nguyen, Neena Kapoor, Katayoun Rezvani, Sattva S. Neelapu & Elizabeth J. Shpall. (2018) Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nature Reviews Clinical Oncology 16:1, pages 45-63.
Crossref
Crossref
Miguel F. Sanmamed & Lieping Chen. (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:2, pages 313-326.
Crossref
Crossref
Aleksei Titov, Alexey Petukhov, Alena Staliarova, Dmitriy Motorin, Emil Bulatov, Oleg Shuvalov, Surinder M. Soond, Mauro Piacentini, Gerry Melino, Andrey Zaritskey & Nickolai A. Barlev. (2018) The biological basis and clinical symptoms of CAR-T therapy-associated toxicites. Cell Death & Disease 9:9.
Crossref
Crossref
Mark A. Perazella & Anushree C. Shirali. (2018) Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future. Journal of the American Society of Nephrology 29:8, pages 2039-2052.
Crossref
Crossref
Danielle S. Burstein, Shannon Maude, Stephen Grupp, Heather Griffis, Joseph Rossano & Kimberly Lin. (2018) Cardiac Profile of Chimeric Antigen Receptor T Cell Therapy in Children: A Single-Institution Experience. Biology of Blood and Marrow Transplantation 24:8, pages 1590-1595.
Crossref
Crossref
Zohreh Sadat Badieyan & Sayed Shahabuddin Hoseini. (2018) Adverse Effects Associated with Clinical Applications of CAR Engineered T Cells. Archivum Immunologiae et Therapiae Experimentalis 66:4, pages 283-288.
Crossref
Crossref
Danielle L Saly & Mark A Perazella. (2018) The adverse kidney effects of cancer immunotherapies. Journal of Onco-Nephrology 2:2-3, pages 56-68.
Crossref
Crossref
Esther Drent, Renée Poels, Manon J. Mulders, Niels W. C. J. van de Donk, Maria Themeli, Henk M. Lokhorst & Tuna Mutis. (2018) Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design. PLOS ONE 13:5, pages e0197349.
Crossref
Crossref
Tiberiu Tat, Huming Li, Catalin-Sorin Constantinescu, Anca Onaciu, Sergiu Chira, Ciprian Osan, Sergiu Pasca, Bobe Petrushev, Vlad Moisoiu, Wilhelm-Thomas Micu, Cristian Berce, Sebastian Tranca, Delia Dima, Ioana Berindan-Neagoe, Jianliang Shen, Ciprian Tomuleasa & Liren Qian. (2018) Genetically enhanced T lymphocytes and the intensive care unit. Oncotarget 9:23, pages 16557-16572.
Crossref
Crossref
Michal P. Kuczma, Zhi-Chun Ding, Tao Li, Tsadik Habtetsion, Tingting Chen, Zhonglin Hao, Locke Bryan, Nagendra Singh, James N. Kochenderfer & Gang Zhou. (2017) The impact of antibiotic usage on the efficacy of chemoimmunotherapy is contingent on the source of tumor-reactive T cells. Oncotarget 8:67, pages 111931-111942.
Crossref
Crossref
Mohanraj Ramachandran, Anna Dimberg & Magnus Essand. (2017) The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells. Seminars in Cancer Biology 45, pages 23-35.
Crossref
Crossref
Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett, Tanya Siddiqi, Julio C. Chavez, Chitra M. Hosing, Armin Ghobadi, Lihua E. Budde, Adrian Bot, John M. Rossi, Yizhou Jiang, Allen X. Xue, Meg Elias, Jeff Aycock, Jeff Wiezorek & William Y. Go. (2017) Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Molecular Therapy 25:1, pages 285-295.
Crossref
Crossref
Axel Schambach & Michael Morgan. 2016. Current Strategies in Cancer Gene Therapy. Current Strategies in Cancer Gene Therapy
17
35
.